Buprenorphine (Suboxone, Sublocade) is a Schedule III partial opioid agonist used for opioid use disorder (OUD) and chronic pain. It works by partially activating mu-opioid receptors with a ceiling effect that limits euphoria and respiratory depression compared to full agonists; naloxone added to Suboxone deters injection misuse. Common side effects include headache, nausea, constipation, and sweating. The black box warning covers life-threatening respiratory depression when combined with benzodiazepines or other CNS depressants — a leading cause of opioid-related overdose deaths.
Buprenorphine
Uses & FDA Indications
Buprenorphine has FDA approval across multiple formulations for two broad therapeutic areas: opioid use disorder (OUD) and chronic pain management. The formulation used determines the indication.
For opioid use disorder: Suboxone (sublingual buprenorphine/naloxone film or tablet), Zubsolv (sublingual tablet), and generic buprenorphine/naloxone are the primary maintenance treatment formulations. Sublocade is a once-monthly subcutaneous extended-release injection approved for patients already stabilized on sublingual buprenorphine. For chronic pain: Belbuca (buccal film) and Butrans (transdermal patch) are approved for severe chronic pain requiring around-the-clock opioid treatment in opioid-tolerant patients.
Off-label applications include acute pain management in opioid use disorder patients (where other opioids are problematic) and neonatal opioid withdrawal syndrome. Buprenorphine is a cornerstone of medications for opioid use disorder (MOUD) and is associated with significantly reduced overdose mortality, improved retention in treatment, and better psychosocial outcomes compared to no medication treatment.
How It Works
Buprenorphine is a partial agonist at the mu-opioid receptor — the same receptor activated by heroin, oxycodone, morphine, and other full agonist opioids. As a partial agonist, it activates the receptor but produces a submaximal response relative to full agonists, and critically, exhibits a ceiling effect: above a certain dose, increasing buprenorphine produces no additional euphoria or respiratory depression. This ceiling effect is the pharmacological basis for its improved safety profile compared to methadone or full agonists.
Buprenorphine's affinity for the mu receptor is extremely high — higher than most full agonists including morphine, oxycodone, and fentanyl. This means buprenorphine can displace these opioids from receptors. In a physically opioid-dependent patient, this displacement is what causes precipitated withdrawal: the partial agonist's weaker activation is insufficient to prevent withdrawal despite occupying the receptors. This is why induction must be timed to when the patient is already in mild-to-moderate opioid withdrawal (COWS score ≥8–12).
The naloxone in Suboxone (buprenorphine/naloxone) serves as an abuse deterrent. When the sublingual film dissolves under the tongue as intended, naloxone is poorly absorbed systemically and has minimal effect — buprenorphine's therapeutic effects predominate. If the film is dissolved in water and injected, naloxone is active intravenously and precipitates immediate withdrawal in opioid-dependent users, discouraging injection misuse.
FDA BLACK BOX WARNING — RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS: Serious, life-threatening, or fatal respiratory depression, coma, and death have occurred in patients taking buprenorphine concurrently with benzodiazepines or other CNS depressants (alcohol, other opioids, muscle relaxants, sleep aids). Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit quantities and ensure patients understand the risks. Monitor closely for respiratory depression.
Side Effects
Common
- Headache — one of the most frequently reported side effects across formulations
- Nausea and vomiting — particularly during induction or dose increases; generally improves with time
- Constipation — a class effect of all opioids including partial agonists; may persist throughout treatment
- Insomnia — sleep disturbance is common, especially early in treatment
- Sweating — particularly nocturnal sweating; a common opioid-class effect
- Oral numbness or tingling — from sublingual dissolving; generally mild
- Injection site reactions (Sublocade) — pain, redness, itching, or nodule formation at the subcutaneous injection site in the abdomen
Serious
- Respiratory depression — despite the ceiling effect, respiratory depression remains possible, particularly when buprenorphine is combined with benzodiazepines, alcohol, or other CNS depressants. The ceiling effect does not eliminate risk — it reduces it compared to full agonists.
- Precipitated opioid withdrawal — if given to a patient who is not sufficiently in opioid withdrawal, buprenorphine's high-affinity partial agonism displaces full agonists and triggers immediate severe withdrawal. COWS assessment before induction is essential.
- Hepatic effects — elevations in liver enzymes have been reported; use with caution in patients with hepatic impairment. Severe hepatic events are rare but have been reported, primarily with intravenous misuse.
- Neonatal opioid withdrawal syndrome — infants born to mothers on buprenorphine maintenance may experience neonatal withdrawal; this is expected and manageable and should not be a reason to discontinue treatment during pregnancy (which carries greater risk)
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Benzodiazepines (diazepam, alprazolam, clonazepam, lorazepam) | Combined CNS and respiratory depression. Most opioid-related overdose deaths involving buprenorphine also involve benzodiazepines. The combination dramatically increases risk of fatal respiratory depression despite buprenorphine's ceiling effect. | CRITICAL — FDA Black Box Warning; avoid if possible; if combination is necessary, minimize doses and duration, monitor closely |
| Alcohol and CNS depressants (muscle relaxants, sleep medications, gabapentinoids) | Additive CNS and respiratory depression, significantly increasing overdose risk. Patients must be counseled to avoid alcohol entirely during treatment. | High — FDA Black Box Warning extends to this class; avoid combination |
| CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit) | Buprenorphine is primarily metabolized by CYP3A4. Inhibitors of this enzyme can substantially increase buprenorphine plasma levels, potentially increasing sedation and respiratory depression risk. | Moderate-High — monitor for increased buprenorphine effects; consider dose adjustment |
| CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) | These drugs accelerate buprenorphine metabolism, potentially reducing plasma levels and therapeutic effectiveness, risking withdrawal in dependent patients. | Moderate — monitor for signs of withdrawal; may require dose adjustment |
| Full opioid agonists (morphine, oxycodone, fentanyl) | Buprenorphine's high receptor affinity can displace full agonists and precipitate withdrawal. Conversely, if a patient on buprenorphine takes a full opioid agonist, the analgesic and euphoric effects may be blunted — though not eliminated, especially with high-potency opioids like fentanyl. | High — avoid routine opioid analgesia in patients on buprenorphine; coordinate with prescriber for surgical or acute pain management |
| MAO inhibitors | Concurrent use with MAOIs may result in serotonin syndrome or opioid toxicity. | High — avoid combination; allow 14-day washout from MAOIs |
Warnings & Contraindications
Contraindications
- Hypersensitivity to buprenorphine or naloxone (for Suboxone formulation)
- Severe respiratory insufficiency (not adequately managed)
- Severe hepatic impairment
Precipitated Withdrawal — Induction Timing
The most critical risk on initiation is precipitated withdrawal. Buprenorphine must only be started when a patient is in moderate opioid withdrawal — typically a COWS (Clinical Opiate Withdrawal Scale) score of 8 or higher. Induction before adequate withdrawal is present displaces full agonists from receptors and substitutes only partial agonism, triggering immediate severe withdrawal symptoms that can last hours. Traditional induction requires being in withdrawal; "low-dose" or "microdose" (Bernese method) induction protocols can avoid precipitated withdrawal by starting at very low buprenorphine doses and slowly escalating — this is increasingly used in patients on fentanyl or methadone where the standard induction window is difficult to achieve.
Schedule III Controlled Status
Buprenorphine is a Schedule III controlled substance. Prescribing for opioid use disorder previously required a federal DEA waiver (the "X-waiver"), but this requirement was eliminated by the Mainstreaming Addiction Treatment (MAT) Act effective 2023 — any DEA-licensed practitioner can now prescribe buprenorphine for OUD without additional certification, though states may have their own requirements.
Check buprenorphine interactions with other medications, including benzodiazepines and CNS depressants.
Check Drug Interactions →Frequently Asked Questions
Is Suboxone a narcotic?
Technically, yes — buprenorphine, the active component in Suboxone, is a Schedule III controlled opioid under federal law and is classified as a narcotic. However, it functions very differently from traditional opioids of abuse. As a partial agonist with a ceiling effect on euphoria and respiratory depression, it stabilizes patients with opioid use disorder rather than producing the intense highs associated with full agonists like heroin or oxycodone. The naloxone added to Suboxone further deters injection misuse. Despite being scheduled, Suboxone is a medically endorsed, evidence-based treatment — not a drug of abuse when used as prescribed.
Does buprenorphine get you high?
In opioid-naive individuals, buprenorphine can produce euphoria similar to other opioids. However, in people with opioid use disorder who have opioid tolerance, the partial agonist ceiling effect means buprenorphine produces limited euphoria — enough to relieve withdrawal symptoms and cravings without the intense high that drives addictive use. The naloxone component of Suboxone is designed to precipitate withdrawal if the film is injected rather than dissolved under the tongue, further reducing misuse potential. Some individuals do misuse buprenorphine, particularly to self-treat withdrawal from other opioids.
How long does Suboxone block opioids?
Buprenorphine's exceptionally high affinity for opioid receptors means it effectively blocks or blunts the effects of other opioids for 24–72 hours after a dose, depending on the amount taken. Its half-life of 24–42 hours allows once-daily or even alternate-day dosing in stable patients. The long-acting injectable buprenorphine (Sublocade) provides sustained opioid blockade for approximately 30 days after a single subcutaneous injection. If another opioid is taken while buprenorphine occupies receptors, the additive effects are reduced — though this is not absolute protection against overdose, especially with high-potency opioids like fentanyl.